INSCRIÇÃO

Critérios para inscrição

As inscrições para o International Symposium on Immunobiologicals são gratuitas e estão abertas tanto para brasileiros quanto para estrangeiros.

Para participar, é pré-requisito ser pesquisador, profissional, estudante ou professor da área de imunobiológicos e afins, proveniente de instituições de produção, fomento, desenvolvimento tecnológico de vacinas, biofármacos ou reativos para diagnóstico, ou da área de saúde pública.

A efetivação da inscrição dará ao participante acesso à plataforma virtual do evento, com direito a participação em todas palestras, visitação à exibição de pôsteres e interação com os demais participantes.

A participação em workshops, mini cursos e webinares pré e pós evento será feita separadamente, com formulários de inscrição independentes para cada atividade, somente para os participantes inscritos no ISI.

A organização poderá recusar a inscrição de qualquer participante que não esteja alinhado com a conduta do simpósio, ou que prejudique ou coloque em risco os demais participantes ou a realização do evento, a qualquer momento, de acordo com seu julgamento.

Programação do 7th ISI

Confira a programação do evento.

Expand All +
  • May 02



  • 08:30 – 09:30 Round table 1A – The challenge of Low Vaccination Coverage Situation in Brazil and Worldwide • Brazil – Ethel Maciel, SVS / Brazilian MoH* • Americas – Jarbas Barbosa, PAHO* • WHO – Samir Sodha, IVB/WHO* Chair: Akira Homma, Fiocruz* 9:30–10:00 Coffee break 10:00–11:00 Round table 1B – How to overcome the low vaccination Coverage Challenges? Brazilian field experiences • Creating connections with vulnerable groups – Oiapoque / Teatro Maiuhi, Elissandra Barros da Silva, Pet Indígena – Unifap* • Strategies to reconquest the high vaccination coverages in Paraíba State, Renata Nóbrega, Health Surveillance Unit from Paraíba* • For the Recovery of the High Vaccination Rates Project in Brazil through solidarity networks, Maria de Lourdes de Sousa Maia, PRCV Bio-Manguinhos* 11:00–11:30 Round table 1C – Challenges and perspectives for SUS to strengthen vaccination in Brazil • Primary health care agenda, Ricardo Gadelha de Abreu, Secretary of Primary Health Care, Ministry of Health* • Health surveillance agenda, Eder Gatti, Director, Department of Immunization and Preventable Diseases, Ministry of Health*

  • – Guided visit to the Museu da Vida and Fiocruz Castle – Guided visit to Bio-Manguinhos’ vaccine and biopharmaceuticals production site

  • 11:40 – 12:10 – Poster pitch
    VACCINATION COVERAGE IN BRAZIL • VAC-06 – Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate, Rita Soares Barbosa Cardona, USP • ORT-18- Human papillomavirus vaccination coverage in Brazilian North Region, 2013-2022, Mateus de Paula Von Glehn, EpiSUS • VAC-18 – Analysis of the possible factors associated with a low vaccination coverage among health Science undergraduates, Camila Costa dos Santos, UFF 12:20 – 12:50 – Poster pitch
    IMMUNE RESPONSE AND COVID-19 • VAC-09- Observational study of immunogenicity, effectiveness and reactogenicity in 6 months to 17 years age group of vaccines against COVID-19, Camila Amormino Corsini, Fiocruz/Minas IRR • IVD-06- New approaches in the detection of neutralizing antibodies using SARS-CoV-2 as a model, Caio Bidueira Denani, Fiocruz/Bio-Manguinhos • VAC-11 – Humoral immune response of allergic subjects vaccinated against COVID-19, Laura Alves Ribeiro Oliveira, Universidade Federal de Uberlândia
    Azul claro

  • Coral da Fiocruz ▪ Carlos Augusto Grabois Gadelha, Brazilian MoH ▪ Mario Santos Moreira, Fiocruz ▪ Maurício Zuma, Bio-Manguinhos ▪ Akira Homma, Coordenador Científico do 7th ISI*

  • Poster Poster Oral Presentation 1 (VAC) • VAC-03 – An alphavirus-derived replicon polyvalent RNA vaccine induces neutralizing antibodies in mice against omicron SARS-CoV-2 variant of concern, Vinicius Pinto Costa Rocha, SENAI CIMATEC
    Poster Oral Presentation 2 (VAC) • VAC-02 – Immunogenicity and protection evaluation of a live attenuated chimeric vaccine for zika virus in mice model, José Henrique Rezende Linhares, Fiocruz/Bio-Manguinhos

  • 14:40 – 15:10 – Poster pitch – VACCINOLOGY • VAC-08 – Integrating Next-Generation Phage Display and bioinformatics approaches for the screening of B-cell epitopes of different antigens using polyclonal sera, Alexsander de Moraes, USP – Faculdade de Medicina de Ribeirão Preto • VAC-07 – ntranasal Vaccinal strategy targeting mucosal surface for methicillin-resistant Staphylococcus aureus (MRSA) decolonization, Juliana Georg da Silva, Fiocruz/Bio-Manguinhos • VAC-13 – Development and comparison of potential DNA and mRNA vaccines for Dengue serotype 2, Sarah Aparecida Rodrigues Sérgio, CT Vacinas – UFMG

  • New technologies for accelerating vaccine development and new delivery methods • Adjuvants – Charles Lutsch, Sanofi* • Vaccine development in 100 days – Ann-Muriel Steff, CEPI* Chair: Sotiris Missailidis, Bio-Manguinhos

  • Vaccine hesitancy and the risk of polio re-emergence • Causes of vaccine hesitancy, data from the study on low vaccine coverage and adverse effects, José Cassio de Moraes* • Risk of Polio re-emergence in Brazil, Luiza Helena Falleiros*

  • May 03


  • Azul

  • Azul

  • – Guided visit to the Museu da Vida and Fiocruz Castle – Guided visit to Bio-Manguinhos’ vaccine and biopharmaceuticals production site

  • 11:40 – 12:10 – Poster pitch
    FROM INFECTIOUS DISEASES TO CANCER – NEW THERAPEUTIC APPROACHES
    • ORT-02 – Improvement CAR-T cell therapy with ultra-fast protocol and IL-15 membrane bound addition, Luiza de Macedo Abdo, INCa • ORT-03 – Evaluation of a betullinic acid nanosystem for cancer therapy, Natália Pereira da Rocha, Fiocruz • ORT-08 – Synthesis of polymeric nanoparticles of a high potency second generation isoniazid derivative aiming tuberculosis treatment via direct delivery to the lung, Frederico Silva Castelo Branco, Fiocruz/Farmanguinhos
    12:20 – 12:50 – Poster pitch
    BIOPHARMACEUTICALS AND CANCER
    • ORT-07 – Anti-her2 CAR-T cells evaluation in a ovarian tumor preclinical model, Emmanuel Arthur Albuquerque Aragao, INCa • BIO-04 – Structural modeling and design of scFv fragments from the antineoplastic antibody Brontictuzumab for enhanced binding to Notch1 NRR region, Aline de Oliveira Albuquerque, Fiocruz Ceará • BIO-08 – Regulation of the epigenetic machinery in pancreatic cancer, Ricardo Alberto Chiong Zevallos, USP

  • Biopharmaceuticals encoded by DNA and RNA • CART Cells to treat cardiac injuries using mRNA, Joel Rurik, University of Pensylvannia* • Next generation lipid nanoparticles technology for extrahepatic delivery of RNA molecules, Jayesh Kulkarn, NanoVation • Revolutionizing Antibody Discovery with Single-Cell Analysis, James Crowe, Vanderbilt Vaccine Center Chair: Patricia Neves, Bio-Manguinhos

  • Poster Oral Presentation 3 (BIO) • BIO-01 – Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells, Najla Santos Pacheco de Campos, Universidade Federal do ABC Poster Oral Presentation 4 (MAN) • MAN-01 – Project For the Recovery of High Vaccination Coverage: innovation in structuring actions to promote vaccination at the local level, Isabel Cristina Alencar De Azevedo, Fiocruz/Bio-Manguinhos

  • 14:40 – 15:10 Poster pitch – NEW THERAPY APPROACHES • BIO-03 – Development and Characterization of Anti-VLA4 Monoclonal Antibody as a Potential Biopharmaceutical for the Treatment of Multiple Sclerosis, Vitória Fernandes de Castro, Fiocruz/Bio-Manguinhos • VAC-10 – Safety and immunogenicity of the anti-cocaine vaccine UFMG-VAC-V4N2 in a non-human primate model, Raissa Lima Gonçalves Pereira, UFMG • BIO-05 – CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy, Thiago Lazari Machado, Fiocruz/Bio-Manguinhos

  • Management of Biotech Development and Production in the 4th Industrial Revolution •First steps on the journey to the future of the productive sector, Igor Calvet, ABDI* •4th Industrial Revolution in Biotech industry, Marcio Freitas, Aché •Applications of 4.0 solutions in the pharmaceutical industry, Fabricio Costa, Deloitte* •4.0 platform for the new Bio-Manguinhos plant, Fernando Serva Cavalcanti Leite, Bio-Manguinhos* Chair: Luiz Alberto Lima*, Bio-Manguinhos

  • May 04


  • Azul claro

  • Azul claro

  • Evolution of the development, regulation and use of biosimilars

  • 11:40 – 12:10 – Poster pitch
    TECHNOLOGICAL DEVELOPMENT AND INNOVATION TO CONTROL TO ENDEMIC INFECTIOUS DISEASES
    • IVD-02 – Kit NAT PLUS HIV/HBV/HCV/Malária Bio-Manguinhos: Innovation and technological upgrade for NAT, Daniele Ramos Rocha, Fiocruz/Bio-Manguinhos • ORT-04 – Evaluation of three antigens for the use in immunochromatographic rapid test for serological diagnosis of Human Visceral Leishmaniasis in Brazil, Allana Kelly Oliveira Dutra, Fiocruz/Bio-Manguinhos • IVD-08- Evaluation of Influenza A and SARS-CoV2 detection using RT-PCR by paired saliva and nasopharyngeal secretions samples, Pedro Henrique Cardoso, Fiocruz/Bio-Manguinhos 12:20 – 12:50 – Poster pitch
    VIRUSES – FROM RAPID TEST TO MULTIPLEX ASSAY
    • IVD-03 – A flow cytometry-based assay to measure neutralizing antibodies against SARS-CoV-2 virus, Veridiane Maria Pscheidt – UFCSPA • ORT-09 – Usefulness of rapid molecular assay to detect hepatitis C virus, Vanessa Duarte da Costa, Fiocruz/IOC • IVD-07 – Development of a multiplex RT-PCR molecular assay for Measles and Rubella viruses detection, Monica Barcellos Arruda, Fiocruz/Bio-Manguinhos

  • Cancer diagnosis and core demands • Diagnostics by sequencing and digital PCR. What can we expect? Ilana Zalcberg, INCa* • Real-time PCR and digital PCR applied to cancer diagnosis, John Young Lee, OPTOLANE Technologies Inc.* Chair: Patricia Alvarez da Silva Baptista, Bio-Manguinhos*

  • Poster Oral Presentation 5 (IVD) • IVD-01 – Detection of Plasmodium spp. in asymptomatic blood donors at Brazilian blood centers by the NAT PLUS HIV/HBV/HCV/MALARIA Bio-Manguinhos kit, Beatriz Vasconcello de Souza Barreto, Fiocruz/Bio-Manguinhos Poster Oral Presentation 6 (ORT) • ORT-01 – A high content image-based assay for detection and measurement of SARS-CoV-2 neutralizing antibodies, Vinicius Pinto Costa Rocha, SENAI CIMATEC

  • 14:40 – 15:10 – Poster pitch – INFECTIOUS DISEASES
    • ORT-05 – Evaluation of mutations in ABCB1 and ABCB11 genes by qPCR and their impact on the clinical evolution of hepatitis C, Leticia Bomfim Campos, Fiocruz/Instituto Oswaldo Cruz • ORT-06 – Thiourea Derivatives with Antimycobacterial and Anti-Inflammatory Activity as an Adjuvant Treatment Strategy for Severe Pulmonary Tuberculosis, Sanderson Dias Calixto, UENF • BIO-02 – Effect of lactoferrin as an immunomodulator and gene regulation of ferritin in different tissues of K18- hACE2 mice infected with SARS-CoV-2, Andrea Marques Vieira Da Silva – Fiocruz/Bio-Manguinhos

  • One Health and preparedness for the next pandemic • A. Alonso Aguirre, Colorado State University* • Mariangela Simão, Instituto Todos Pela Saúde* • Ann-Muriel Steff, CEPI* • Patricia Oliveira Pereira Tagliari, Anvisa* Chair: Akira Homma, Bio-Manguinhos

  • ▪ Poster Award Independent Committee Event close-up remarks Akira Homma, Bio-Manguinhos
    Cinza escuro